Loading...
•
Dec 31, 2022
DBV Technologies Q4 2022 Earnings Report
DBV Technologies reported full year 2022 financial results and provided a business update.
Key Takeaways
DBV Technologies reported full year 2022 financial results, highlighting the completion of the EVOLVE study and a cash and cash equivalents balance of $209.2 million as of December 31, 2022.
DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch.
The EVOLVE study evaluated the Instructions for Use (IFU) and ease of use for the modified Viaskin Peanut patch.
DBV had $209.2 million in Cash and Cash Equivalents at December 31, 2022.
The company's activities and expenditures in the fourth quarter were in line with expectations, reflecting DBV’s expense discipline.
DBV Technologies
DBV Technologies
Forward Guidance
This press release may contain forward-looking statements and estimates, including statements regarding DBV’s forecast of its cash runway, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies, and the outcome of any litigation.